VKTX PE Ratio & Valuation,Is VKTX Overvalued

VKTX Relative Valuation

VKTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VKTX is overvalued; if below, it's undervalued.

Historical Valuation

Viking Therapeutics Inc (VKTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -17.55. The fair price of Viking Therapeutics Inc (VKTX) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：35.72

Fair

-9.15

-8.86

EV/EBITDA

Viking Therapeutics Inc. (VKTX) has a current EV/EBITDA of -8.86. The 5-year average EV/EBITDA is -12.23. The thresholds are as follows: Strongly Undervalued below -39.62, Undervalued between -39.62 and -25.93, Fairly Valued between 1.46 and -25.93, Overvalued between 1.46 and 15.15, and Strongly Overvalued above 15.15. The current Forward EV/EBITDA of -8.86 falls within the Historic Trend Line -Fairly Valued range.

-7.53

EV/EBIT

Viking Therapeutics Inc. (VKTX) has a current EV/EBIT of -7.53. The 5-year average EV/EBIT is -11.47. The thresholds are as follows: Strongly Undervalued below -37.25, Undervalued between -37.25 and -24.36, Fairly Valued between 1.42 and -24.36, Overvalued between 1.42 and 14.31, and Strongly Overvalued above 14.31. The current Forward EV/EBIT of -7.53 falls within the Historic Trend Line -Fairly Valued range.

0.00

Viking Therapeutics Inc. (VKTX) has a current PS of 0.00. The 5-year average PS is 209.94. The thresholds are as follows: Strongly Undervalued below -963.52, Undervalued between -963.52 and -376.79, Fairly Valued between 796.67 and -376.79, Overvalued between 796.67 and 1383.40, and Strongly Overvalued above 1383.40. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-10.18

P/OCF

Viking Therapeutics Inc. (VKTX) has a current P/OCF of -10.18. The 5-year average P/OCF is -18.72. The thresholds are as follows: Strongly Undervalued below -57.89, Undervalued between -57.89 and -38.30, Fairly Valued between 0.86 and -38.30, Overvalued between 0.86 and 20.44, and Strongly Overvalued above 20.44. The current Forward P/OCF of -10.18 falls within the Historic Trend Line -Fairly Valued range.

-12.56

P/FCF

Viking Therapeutics Inc. (VKTX) has a current P/FCF of -12.56. The 5-year average P/FCF is -15.22. The thresholds are as follows: Strongly Undervalued below -42.61, Undervalued between -42.61 and -28.91, Fairly Valued between -1.52 and -28.91, Overvalued between -1.52 and 12.18, and Strongly Overvalued above 12.18. The current Forward P/FCF of -12.56 falls within the Historic Trend Line -Fairly Valued range.

Viking Therapeutics Inc (VKTX) has a current Price-to-Book (P/B) ratio of 5.63. Compared to its 3-year average P/B ratio of 6.38 , the current P/B ratio is approximately -11.71% higher. Relative to its 5-year average P/B ratio of 4.53, the current P/B ratio is about 24.44% higher. Viking Therapeutics Inc (VKTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -3.41%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -7.26% , the current FCF yield is about -100.00% lower.

5.63

P/B

Median3y

6.38

Median5y

4.53

-5.50

FCF Yield

Median3y

-3.41

Median5y

-7.26

Competitors Valuation Multiple

The average P/S ratio for VKTX's competitors is 0.00, providing a benchmark for relative valuation. Viking Therapeutics Inc Corp (VKTX) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of VKTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of VKTX in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Viking Therapeutics Inc (VKTX) currently overvalued or undervalued?

What is Viking Therapeutics Inc (VKTX) fair value?

VKTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Viking Therapeutics Inc (VKTX) is between to according to relative valuation methord.

How does VKTX's valuation metrics compare to the industry average?

What is the current P/B ratio for Viking Therapeutics Inc (VKTX) as of Dec 17 2025?

As of Dec 17 2025, Viking Therapeutics Inc (VKTX) has a P/B ratio of 5.63. This indicates that the market values VKTX at 5.63 times its book value.

What is the current FCF Yield for Viking Therapeutics Inc (VKTX) as of Dec 17 2025?

As of Dec 17 2025, Viking Therapeutics Inc (VKTX) has a FCF Yield of 0.00%. This means that for every dollar of Viking Therapeutics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Viking Therapeutics Inc (VKTX) as of Dec 17 2025?

As of Dec 17 2025, Viking Therapeutics Inc (VKTX) has a Forward P/E ratio of -9.15. This means the market is willing to pay $-9.15 for every dollar of Viking Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Viking Therapeutics Inc (VKTX) as of Dec 17 2025?

As of Dec 17 2025, Viking Therapeutics Inc (VKTX) has a Forward P/S ratio of 0.00. This means the market is valuing VKTX at $0.00 for every dollar of expected revenue over the next 12 months.

VKTX Valuation